{"product_id":"bilcare-business-model-canvas","title":"Bilcare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBilcare Business Model Canvas: Downloadable Strategic Blueprint for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Bilcare’s business model — a concise, actionable Business Model Canvas that reveals how the company creates value, scales operations, and captures market share; ideal for investors, consultants, and founders seeking a ready-to-use, downloadable analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with global and regional pharmaceutical manufacturers drive co-development of specialized packaging; Bilcare partners with firms representing over 40% of the top 50 pharma by revenue to tailor barrier films and blister systems. By syncing production to drug stability and shelf-life needs and embedding with client R\u0026amp;D, Bilcare cut regulator rework rates to 3% in 2024 and supports products achieving +24-month shelf lives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-term supply contracts for specialized polymers, aluminum foils, and chemical additives keep Bilcare’s barrier-film quality stable; in 2025 the company targets 95% on-time resin deliveries to avoid line downtime and roughly 18% cost reduction from volume pricing.\u003c\/p\u003e\n\u003cp\u003eDuring restructuring, securing high-grade resins is top priority to prevent bottlenecks; joint quality-control protocols with key suppliers cover incoming QA, 99.8% film integrity specs, and quarterly audits tied to SLAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with Clinical Research Organizations (CROs) let Bilcare provide secure, compliant, and blinded packaging for investigational medicinal products, a service segment growing ~8% CAGR and worth about $4.2bn in clinical supplies globally in 2024; tighter CRO ties could lift Bilcare’s clinical logistics share from an estimated 6% to ~10% within 3 years, adding roughly $25–40m annual revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and IP Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with technology firms lets Bilcare embed anti-counterfeiting and track-and-trace features into packaging, matching pharma serialization standards (eg, EU Falsified Medicines Directive) and cutting counterfeit risk; such deals helped similar suppliers grow secure-revenue share by ~12% in 2024.\u003c\/p\u003e\n\u003cp\u003eJoint ventures and licensing lower R\u0026amp;D spend—Bilcare can deploy digital authentication tools while preserving margins in the high-security pharma market, where premium pricing lifted security-packaging ASPs ~8% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrates serialization \u0026amp; track-and-trace\u003c\/li\u003e\n\u003cli\u003eMatches EU\/FDA compliance\u003c\/li\u003e\n\u003cli\u003eReduces internal R\u0026amp;D costs via licensing\/JV\u003c\/li\u003e\n\u003cli\u003eSupports ~12% secure-revenue growth (2024)\u003c\/li\u003e\n\u003cli\u003eHelps capture ~8% higher ASPs for security packs (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Restructuring Advisors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGiven Bilcare's 2024 net debt of about $120m and covenant breaches in H2 2023, ongoing partnerships with debt-restructuring specialists and banks are pivotal to manage the balance sheet and secure the ~€40–60m capital infusion estimated as needed to stabilise operations.\u003c\/p\u003e\n\u003cp\u003eThese advisors also validate going-concern assumptions for investors; in 2025 lender-led restructuring workstreams aim to extend maturities by 24–36 months and cut interest costs by ~2 percentage points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt ~ $120m (2024)\u003c\/li\u003e\n\u003cli\u003eCapital need estimate €40–60m\u003c\/li\u003e\n\u003cli\u003eMaturity extension target 24–36 months\u003c\/li\u003e\n\u003cli\u003eInterest-cost reduction ~2 pp\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop‑50 pharma ties drive 12% secure‑pack growth, 3% rework; €40–60m recap target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships with top pharma (40% of top50 clients), CROs, tech licensors, and suppliers secure supply, compliance, and anti-counterfeit features—cutting regulator rework to 3% (2024), supporting +24‑month shelf lives, and enabling ~8–12% premium secure‑pack revenue growth in 2024; lender and advisor deals target €40–60m recap and 24–36 month maturity relief.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑50 pharma coverage\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulator rework rate\u003c\/td\u003e\n\u003ctd\u003e3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecure‑pack ASP uplift\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecure‑revenue growth\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital need\u003c\/td\u003e\n\u003ctd\u003e€40–60m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaturity extension target\u003c\/td\u003e\n\u003ctd\u003e24–36 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Bilcare detailing its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting real-world operations, competitive advantages, SWOT-linked insights, and designed for presentations, investor discussions, and strategic validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Bilcare’s packaging and pharma services strategy into a digestible one-page canvas for quick review, saving hours of structuring and enabling collaborative adaptation for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Packaging Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBilcare’s core activity is manufacturing high-barrier multi-layer films and foils for sensitive pharmaceuticals, notably blister films that cut moisture, light and oxygen transmission to \u0026lt;0.1 g\/m2\/day; in 2024 packaging sales totaled about $230m with 18% YoY growth. Production follows global pharmacopeia specs (USP, EP) and ISO 15378 GMP for primary packaging to ensure stability and regulatory acceptance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBilcare’s R\u0026amp;D targets novel polymer blends and sustainable packaging to meet EU single-use plastics and UK Extended Producer Responsibility rules; R\u0026amp;D spend rose to €18.4m in FY2024 (3.2% of revenue) to cut plastic mass by 25% per pack by 2027. This drives materials that boost barrier performance and claims premium pricing, key to regaining ~6–8% share in premium pharmaceutical and e-commerce packaging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Supply Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical trial supply management coordinates packaging, labeling, and global distribution across phases I–III, using validated cold-chain and blinding processes; industry average error rate must stay below 0.1% and recent CRO benchmarks show 98.5% on‑time delivery. Bilcare runs GMP-compliant inventory systems with batch traceability and real‑time expiry controls to protect data integrity and patient safety, cutting lost-dose events by ~45% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous monitoring of production ensures each batch of Bilcare pharma packaging meets international safety standards; in 2024 Bilcare's QC rejection rate stayed below 0.6%, sustaining supply to clients in 42 countries.\u003c\/p\u003e\n\u003cp\u003eRigorous testing for chemical migration and physical durability protects patients and kept Bilcare’s compliance spend at ~3.2% of revenue in FY2024 to retain FDA and EMA approvals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQC rejection rate: 0.6% (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance spend: ~3.2% of revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eMarkets served: 42 countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Revitalization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eActive rebuilding of Bilcare’s sales pipeline prioritizes re-establishing brand trust via trade shows and targeted outreach to former and potential healthcare clients, aiming to show renewed stability and technical capability.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Bilcare targets a 30% sales recovery vs 2019 levels, plans 12 industry events and direct outreach to 450 accounts to drive MQLs and rebuild revenue momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% sales recovery target vs 2019\u003c\/li\u003e\n\u003cli\u003e12 trade shows planned in 2025\u003c\/li\u003e\n\u003cli\u003e450 former\/potential clients targeted\u003c\/li\u003e\n\u003cli\u003eFocus: stability, technical capability, healthcare trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBilcare posts $230M packaging sales, 18% growth; R\u0026amp;D trims plastic 25% by 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBilcare makes high-barrier pharma films\/foils (blister barrier \u0026lt;0.1 g\/m2\/day); 2024 packaging sales ~$230m (18% YoY); QC rejection 0.6%; compliance spend ~3.2% revenue; R\u0026amp;D €18.4m (3.2% revenue) to cut plastic mass 25% by 2027; 2025 targets: 30% sales recovery vs 2019, 12 trade shows, 450 accounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePackaging sales\u003c\/td\u003e\n\u003ctd\u003e$230m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQC rejection\u003c\/td\u003e\n\u003ctd\u003e0.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e3.2% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€18.4m (3.2% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlastic reduction target\u003c\/td\u003e\n\u003ctd\u003e25% by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 sales recovery\u003c\/td\u003e\n\u003ctd\u003e30% vs 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\/accounts\u003c\/td\u003e\n\u003ctd\u003e12 shows \/ 450 accounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Bilcare Business Model Canvas—not a sample or mockup—and exactly matches the file delivered after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order you’ll receive this same professional, fully editable Business Model Canvas in the provided formats, ready to present, edit, and apply without alterations or hidden content.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749342097785,"sku":"bilcare-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bilcare-business-model-canvas.png?v=1772214217","url":"https:\/\/matrixbcg.com\/products\/bilcare-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}